Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kamal Baig

Internal Medicine Abingdon, MD Medical Doctor

NPI 1588026710 CMS profile 11423212

100 Walter Ward Blvd Ste 100, Abingdon, MD 21009

Open in the dashboard

General payments

$4,755

178 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kamal Baig of Abingdon, MD is reported in the CMS Open Payments database as having received $4,755 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,314 70
2024 General $1,004 40
2023 General $1,153 57
2022 General $284 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kamal Baig
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kamal Baig were reported at $2,314. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kamal Baig Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $284 $141 $42–$496 $149
2023 $1,153 $149 $45–$519 $160
2024 $1,004 $154 $47–$537 $164
2025 $2,314 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $984 54 payments
  2. Janssen Biotech, Inc. $576 19 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $541 20 payments
  4. Madrigal Pharmaceuticals $403 4 payments
  5. QOL Medical, LLC $387 11 payments
  6. Regeneron Healthcare Solutions, Inc. $372 16 payments
  7. Ardelyx, Inc. $327 9 payments
  8. Medtronic, Inc. $159 3 payments
  9. Celgene Corporation $144 7 payments
  10. Boston Scientific Corporation $115 1 payment
  11. Other $748 34 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,755 178 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $466 13 payments
  2. ENTYVIO $423 15 payments
  3. REZDIFFRA $403 4 payments
  4. Sucraid $387 11 payments
  5. CREON $357 21 payments
  6. LINZESS $343 20 payments
  7. IBSRELA $327 9 payments
  8. MAVYRET $228 12 payments
  9. STELARA $209 11 payments
  10. DUPIXENT $205 9 payments
  11. Other $2,180 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

566

Median for Gastroenterology: 569

Drug cost

$150,568

Median for Gastroenterology: $104,976

Branded share of claims

36.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 11 $74,515
Linzess Linaclotide Brand 25 $35,851
Creon Lipase/Protease/Amylase Brand 13 $22,255
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 92 $5,717
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 31 $5,181
Colestipol Hcl Generic 51 $2,140
Omeprazole Generic 136 $1,494
Ondansetron Hcl Generic 13 $893
Pantoprazole Sodium Generic 67 $741
Famotidine Generic 69 $732

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$94,095

Medicare's payments for the services billed

Medicare patients

497

Average age 73

Services billed

813

262 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 41%
Ischemic heart disease 39%
Chronic kidney disease 32%
Depression 28%
COPD 26%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $210
$210 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $55
  • GENZYME CORPORATION $53
$108 — —
MAVYRET
  • AbbVie, Inc. $74
$74 — —
EOHILIA
  • Takeda Pharmaceuticals U.S.A., Inc. $72
$72 — —
STELARA
  • Janssen Biotech, Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record